Monitoring gastric cancer progression with circulating tumour DNA

Hamakawa, Takuya; Kukita, Yoji; Kurokawa, Yukinori; Miyazaki, Yasuhiro; Takahashi, Tsuyoshi; Yamasaki, Makoto; Miyata, Hiroshi; Nakajima, Kiyokazu; Taniguchi, Koki; Takiguchi, Shuji; Mori, Masaki; Doki, Yuichiro; Kato, Kikuya

doi:10.1038/bjc.2014.609

Cited by 89 publications

(80 citation statements)

References 13 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Detection of cell-free DNA was first described in 1987 by Stroun and collegues (8), and numerous articles were published in the past few years, indicative of a growing interest in this noninvasive diagnostic method (9)(10)(11)(12)(13)(14)(15)(16)(17)(18). Potential application scenarios include using ctDNA to supplement or substitute for tissue biopsies, especially in cases where tissue biopsies are risky or the quantity/quality of the tissue biopsied does not allow testing, and to use repeat sampling and genomic profiling to detect tumor evolution, response, and resistance (6,(19)(20)(21).…”

Section: Introductionmentioning

confidence: 99%

Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients

Schwaederlé¹,

Husain²,

Fanta³

et al. 2016

Clinical Cancer Research

123

124

View full text Add to dashboard Cite

Purpose: There is a growing interest in using circulating tumor DNA (ctDNA) testing in patients with cancer. Experimental Design: A total of 168 patients with diverse cancers were analyzed. Patients had digital next-generation sequencing (54 cancer-related gene panel including amplifications in ERBB2, EGFR, and MET) performed on their plasma. Type of genomic alterations, potential actionability, concordance with tissue testing, and patient outcome were examined. Results: Fifty-eight percent of patients (98/168) had ≥1 ctDNA alteration(s). Of the 98 patients with alterations, 71.4% had ≥ 1 alteration potentially actionable by an FDA-approved drug. The median time interval between the tissue biopsy and the blood draw was 2.7 months for patients with ≥ 1 alteration in common compared with 14.4 months (P = 0.006) for the patients in whom no common alterations were identified in the tissue and plasma. Overall concordance rates for tissue and ctDNA were 70.3% for TP53 and EGFR, 88.1% for PIK3CA, and 93.1% for ERBB2 alterations. There was a significant correlation between the cases with ≥ 1 alteration with ctDNA ≥ 5% and shorter survival (median = 4.03 months vs. not reached at median follow-up of 6.1 months; P < 0.001). Finally, 5 of the 12 evaluable patients (42%) matched to a treatment targeting an alteration(s) detected in their ctDNA test achieved stable disease ≥ 6 months/partial remission compared with 2 of 28 patients (7.1%) for the unmatched patients, P = 0.02. Conclusions: Our initial study demonstrates that ctDNA tests provide information complementary to that in tissue biopsies and may be useful in determining prognosis and treatment. Clin Cancer Res; 22(22); 5497–505. ©2016 AACR.

show abstract

Section: Introductionmentioning

confidence: 99%

Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients

Schwaederlé¹,

Husain²,

Fanta³

et al. 2016

Clinical Cancer Research

123

124

View full text Add to dashboard Cite

show abstract

“…With the advent of new sequencing technologies and analytic techniques, the ability to detect circulating tumor-specific DNA (ctDNA), often referred to as the "liquid biopsy", has evolved. The measurement of ctDNA has been shown to be an accurate reflection of disease presence and tumor evolution in several cancer types including breast, lung, colon, and stomach cancers [8][9][10][11][12]. Previous studies in gynecologic malignancies have primarily evaluated the presence of ctDNA at a single time point using pelvic washes, ascites, serum and plasma [13][14][15].…”

Section: Introductionmentioning

confidence: 99%

Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers

Pereira

Vanegas

Anand

et al. 2016

Gynecologic Oncology

View full text Add to dashboard Cite

“…CNAs have become prominent due to their potential use as surrogate indicators for disease monitoring by early identification of disease progression and recurrence (32)(33)(34)(35). In addition, CNAs have been identified as useful for monitoring tumor burden (36), are associated with minimal residual disease (37), tumor heterogeneity (38), detecting resistance to therapy (39), and also proven to be effective in the early diagnosis of different types of cancer (35), as schematically represented in Fig.…”

Section: Applications Of Cnasmentioning

confidence: 99%